BRPI0716455A2 - Desenvolvimento de componentes de vacina do vírus da dengue - Google Patents

Desenvolvimento de componentes de vacina do vírus da dengue

Info

Publication number
BRPI0716455A2
BRPI0716455A2 BRPI0716455-6A2A BRPI0716455A BRPI0716455A2 BR PI0716455 A2 BRPI0716455 A2 BR PI0716455A2 BR PI0716455 A BRPI0716455 A BR PI0716455A BR PI0716455 A2 BRPI0716455 A2 BR PI0716455A2
Authority
BR
Brazil
Prior art keywords
dengue virus
virus vaccine
vaccine components
components development
development
Prior art date
Application number
BRPI0716455-6A2A
Other languages
English (en)
Inventor
Stephen S Whitehead
Joseph E Blaney
Brian R Murphy
Original Assignee
Us Dept Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Dept Health filed Critical Us Dept Health
Priority to BR122020023372-9A priority Critical patent/BR122020023372B1/pt
Publication of BRPI0716455A2 publication Critical patent/BRPI0716455A2/pt
Publication of BRPI0716455A8 publication Critical patent/BRPI0716455A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0716455A 2006-08-15 2007-08-15 desenvolvimento de componentes de vacina do vírus da dengue BRPI0716455A8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020023372-9A BR122020023372B1 (pt) 2006-08-15 2007-08-15 Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83772306P 2006-08-15 2006-08-15
PCT/US2007/076004 WO2008022196A2 (en) 2006-08-15 2007-08-15 Development of dengue virus vaccine components

Publications (2)

Publication Number Publication Date
BRPI0716455A2 true BRPI0716455A2 (pt) 2014-03-04
BRPI0716455A8 BRPI0716455A8 (pt) 2019-01-15

Family

ID=39083099

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0716455A BRPI0716455A8 (pt) 2006-08-15 2007-08-15 desenvolvimento de componentes de vacina do vírus da dengue
BR122020023372-9A BR122020023372B1 (pt) 2006-08-15 2007-08-15 Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020023372-9A BR122020023372B1 (pt) 2006-08-15 2007-08-15 Vírus da dengue do tipo 3 (den3) atenuado e composição imunogênica

Country Status (15)

Country Link
US (9) US8337860B2 (pt)
EP (2) EP2589602B1 (pt)
CN (2) CN103602689B (pt)
AU (1) AU2007285929B2 (pt)
BR (2) BRPI0716455A8 (pt)
CA (2) CA3004991C (pt)
CY (1) CY1118003T1 (pt)
DK (2) DK2589602T3 (pt)
ES (1) ES2585553T3 (pt)
HU (1) HUE029333T2 (pt)
LT (1) LT2589602T (pt)
PL (1) PL2589602T3 (pt)
PT (1) PT2589602T (pt)
SI (1) SI2589602T1 (pt)
WO (1) WO2008022196A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903126C (en) * 2002-01-10 2020-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
ATE481982T1 (de) * 2002-05-03 2010-10-15 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
PL2589602T3 (pl) 2006-08-15 2016-11-30 Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi
AU2010256845B2 (en) * 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
US9878031B2 (en) 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
EP2968516B1 (en) * 2013-03-15 2022-01-12 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
JP2016523251A (ja) 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
JP6671364B2 (ja) * 2014-11-02 2020-03-25 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル ワクチンおよび診断開発のための組換えデングウイルスについての方法および組成物
ES2981476T3 (es) * 2014-12-22 2024-10-09 Merck Sharp & Dohme Llc Composiciones de vacunas contra el virus del dengue y métodos de uso de las mismas
US9730989B2 (en) 2015-07-02 2017-08-15 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
CA2999881A1 (en) 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
WO2017056101A1 (en) 2015-09-30 2017-04-06 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
CA3016697A1 (en) 2016-03-11 2017-09-14 The Johns Hopkins University Live attenuated zika virus vaccine
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
BR112019016309A2 (pt) * 2017-02-14 2020-03-31 The Board Of Regents Of The University Of Texas System Vírus da zika atenuado vivo com deleção 3'utr, vacina contendo o mesmo e uso da mesma
US10240130B2 (en) 2017-02-15 2019-03-26 The Board Of Regents Of The University Of Texas System CDNA clone-launched platform for high-yield production of inactivated zika virus
WO2019112921A1 (en) 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
BR112022001476A2 (pt) 2019-08-16 2023-10-03 Takeda Vaccines Inc Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit
US20240226338A9 (en) * 2021-02-26 2024-07-11 Duke University Compositions For and Methods of Improving Gene Therapy
US20240150729A1 (en) * 2021-03-19 2024-05-09 Merck Sharp & Dohme Llc A closed-system upstream manufacturing process for dengue virus production
JP2025508605A (ja) * 2022-02-22 2025-03-26 フートル バイオ エルティーディーエー． 次世代ｍＲＮＡワクチン
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
ATE481982T1 (de) * 2002-05-03 2010-10-15 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
WO2006036233A1 (en) * 2004-06-14 2006-04-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services West nile viruses with mutations in the 3’ terminal stem and loop secondary structure for use as live virus vaccines
PL2589602T3 (pl) * 2006-08-15 2016-11-30 Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi

Also Published As

Publication number Publication date
EP2589602A2 (en) 2013-05-08
USRE46042E1 (en) 2016-06-28
US10724007B2 (en) 2020-07-28
US20220251521A1 (en) 2022-08-11
LT2589602T (lt) 2016-10-10
US10160957B2 (en) 2018-12-25
EP2054428A2 (en) 2009-05-06
US12203100B2 (en) 2025-01-21
US8337860B2 (en) 2012-12-25
US20190119654A1 (en) 2019-04-25
US20100104598A1 (en) 2010-04-29
DK2054428T3 (da) 2013-08-26
ES2585553T3 (es) 2016-10-06
EP2589602A3 (en) 2013-10-09
PL2589602T3 (pl) 2016-11-30
WO2008022196A3 (en) 2009-03-12
CN103602689B (zh) 2016-08-24
CN103602689A (zh) 2014-02-26
WO2008022196A2 (en) 2008-02-21
CN101657463B (zh) 2013-09-18
AU2007285929B2 (en) 2013-09-05
EP2589602B1 (en) 2016-04-06
CA2661296A1 (en) 2008-02-21
CA3004991A1 (en) 2008-02-21
CN101657463A (zh) 2010-02-24
US20130089567A1 (en) 2013-04-11
EP2054428B1 (en) 2013-06-05
US20240084269A1 (en) 2024-03-14
US9090873B2 (en) 2015-07-28
HUE029333T2 (en) 2017-03-28
US11746335B2 (en) 2023-09-05
CY1118003T1 (el) 2017-05-17
SI2589602T1 (sl) 2016-08-31
PT2589602T (pt) 2016-07-13
CA2661296C (en) 2018-06-26
DK2589602T3 (en) 2016-07-25
US11332722B2 (en) 2022-05-17
US20180171308A1 (en) 2018-06-21
AU2007285929A1 (en) 2008-02-21
BRPI0716455A8 (pt) 2019-01-15
CA3004991C (en) 2022-08-30
BR122020023372B1 (pt) 2021-11-30
AU2007285929A2 (en) 2009-04-23
US20250236848A1 (en) 2025-07-24
EP2054428B9 (en) 2013-11-13
US20200318083A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
BRPI0716455A2 (pt) Desenvolvimento de componentes de vacina do vírus da dengue
NO2021010I1 (no) telostritat ethyl
BRPI0716483A2 (pt) inibidores do vírus da hepatite c
ATE450271T1 (de) Impfstoff
DK3192874T3 (da) Virusoprensning
DK1968631T3 (da) Vaccine
PL2281830T3 (pl) Szczepionka przeciw wirusowi ospy wietrznej i półpaśca
DK2066354T3 (da) Norovirus vaccine formuleringer
DK1926496T3 (da) PCV-2-vaccine
CR10571A (es) Vacuna virica recombinante
DK2051744T3 (da) Steriliseringsanordning
DK2069335T3 (da) Pyridin-3-ylderivater som immunomoduleringsmidler
BRPI0716193A2 (pt) Replicon derivado de potexvírus
BRPI0821252A2 (pt) Anticorpos ao vírus da hepatite c
BRPI0821034A2 (pt) Vírus influenza modificado
EP2198016A4 (en) ADENO ASSOCIATED SWINE VIRUS
EP1917040A4 (en) POLYVALENT VACCINE
EP2065801A4 (en) EMULATOR
DE502007001364D1 (de) Tevorrichtung
ZA200809056B (en) Influenza virus vaccine
DK2422810T3 (da) Influenzavaccine
DE602006020744D1 (de) Fertigspritze
EP2061502A4 (en) CARBOHYDRATE-BASED VACCINES FOR HLV
DE602007000237D1 (de) Projektionsvorrichtung
BRPI0923034A2 (pt) terapia de combinação para virus da hepatite c

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]